Spots Global Cancer Trial Database for 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
Official Title: An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics
Study ID: NCT02355574
Conditions
Interventions
Study Description
Brief Summary: The INTEGRATE Registry Study follows patients with cutaneous melanoma who have had the DecisionDx-Melanoma gene expression assay performed. Data will be collected through review of medical records from clinical visits with physician. The purpose is to document the clinical application of results obtained from the DecisionDx- Melanoma multi-gene assay and to track outcomes of patients for whom DecisionDx-Melanoma testing has been completed. Additionally the study will assess the health economic impact of DecisionDx-Melanoma testing as it relates to the Melanoma population.
Detailed Description:
Eligibility
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Northside Hospital, Atlanta, Georgia, United States
University of Louisville, Louisville, Kentucky, United States
Saint Louis University, Saint Louis, Missouri, United States
Contact Details
Name: Robert Cook, PhD
Affiliation: Castle Biosciences Inc.
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
